Durham-based Atsena Therapeutics has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for ATSN-201, its gene therapy product for the ...

Philikos announces initiation of clinical Phase 1/2 study with T-Guard® in patients with systemic sclerosisNIJMEGEN, the Netherlands, May 20, 2025 (GLOBE NEWSWIRE) -- Philikos B.V., a Dutch ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 7% in the afternoon session after the FDA ...

Personalized medicine is already a reality in clinical practice, and CAR-T cell therapy is one of its most promising tools.